Full-Time

Facilities & Maintenance Manager

Harrow

Harrow

201-500 employees

Compounds ophthalmic formulations; markets branded drugs

No salary listed

Stanhope, NJ, USA

In Person

Category
Facilities Operations (2)
,
Requirements
  • Bachelor’s degree in Mechanical or Electrical Engineering preferred; equivalent hands-on experience considered
  • Minimum 5 years in GMP pharmaceutical manufacturing
  • Minimum 3 years managing maintenance teams in sterile or regulated environments
  • Demonstrated hands-on troubleshooting of manufacturing equipment and critical utilities
  • Direct experience managing CMMS systems (BMRAM or equivalent)
  • Experience overseeing environmental monitoring systems (Lighthouse or equivalent)
  • Strong knowledge of HVAC, cleanroom classifications, utilities, and GMP documentation practices
  • Experience supporting regulatory inspections
  • Commitment and drive to improve manufacturing operations
  • Perform other duties, as assigned
Responsibilities
  • Develop and lead maintenance team through direct floor engagement, accountability, training, and performance management
  • Full ownership of site-wide maintenance across manufacturing, filling, packaging, utilities, and infrastructure for 503A and 503B operations
  • Ensure >98–100% on-time preventive and predictive maintenance execution; drive rapid response to equipment failures
  • Lead hands-on troubleshooting of critical systems including HVAC, cleanrooms, water for Injection, compressed gases, and sterile processing equipment
  • Own and manage the complete calibration program; maintain 100% compliance and audit readiness
  • Investigate out-of-tolerance and equipment-related deviations; implement effective root cause and CAPA solutions
  • Serve as system owner for BMRAM (CMMS); ensure accurate asset records, timely work order closure, KPI tracking, and data integrity
  • Own Lighthouse environmental monitoring system; ensure continuous ISO compliance, alarm functionality, trend review, and excursion management
  • Maintain validated state of facilities, utilities, and monitoring systems; support inspections as technical SME
  • Lead capital projects from specification through commissioning (URS, FAT, SAT, IOQ, PQ) with direct contractor oversight
  • Control maintenance and calibration budgets while optimizing spare parts inventory and reliability metrics (MTBF, downtime reduction)
  • Drive continuous improvement initiatives using Lean/Kaizen to enhance uptime, throughput, and GMP compliance
  • Develop and implement solutions to difficult problems, manage outside contractors and be on call for emergencies
  • Manage spare parts inventory to balance cost control with operational reliability
  • Ensure facility and utility systems consistently meet ISO classifications, pressure cascades, and environmental control requirements
  • Lead change management, risk assessments (FMEA), and impact evaluations related to facility, equipment, and utility modifications
  • Coordinate and oversee third-party contractors and service providers to ensure GMP-compliant execution and documentation
  • Partner cross-functionally with Operations, Quality, Validation, and Supply Chain to align maintenance strategy with production readiness and business continuity objectives

Harrow focuses on eyecare pharmaceuticals, combining a compounding business (ImprimisRx) with a portfolio of FDA-approved branded drugs and biosimilars, plus biotech investments. Its products include customized compounded sterile and topical eye medications delivered directly to physicians and patients, alongside branded drugs acquired from other companies. The company differentiates itself by integrating a direct-to-physician compounding platform with an expanding branded drug portfolio, biosimilars, and owned production and distribution facilities across all 50 states. Its goal is to provide accessible, high-quality eye medications and grow its commercial and biotech assets to serve surgeons, hospitals, and patients nationwide.

Company Size

201-500

Company Stage

IPO

Headquarters

Nashville, Tennessee

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • VEVYE reached 14% market share with 25% sequential prescription growth in Q1 2026.
  • TRIESENCE unit volume surged 136% year-over-year; BYOOVIZ and IOPIDINE J-code launches in H2 2026.
  • Doubled sales force and $250M debt raise fund aggressive commercial expansion through 2026.

What critics are saying

  • Nordic Pharma authorized generic Maxitrol launch April 2025 erodes $20.8M branded pricing power.
  • VEVYE high-deductible patient mix caused $8M Q1 2026 revenue hit; recurrence threatens guidance.
  • MELT-300 NDA submission H1 2027 faces 30% industry Phase 3 failure rate; delays H2 2028 launch.

What makes Harrow unique

  • Only national-scale FDA-registered compounding facility for sterile ophthalmic formulations.
  • Integrated model combines compounding, branded acquisitions, and biotech incubation in ophthalmology.
  • CEO Mark Baum's pharmacy background drives accessible pricing strategy versus traditional pharma.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Harrow who can refer or advise you

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-15%

1 year growth

-15%

2 year growth

-15%
Simply Wall St
Mar 26th, 2026
How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth

Harrow, Inc. recently completed a private fixed‑income offering of US$50,000,000 in 8.625% senior unsecured notes due 2030, callable and guaranteed by its wholly owned domestic restricted subsidiaries, under Regulation S and Rule 144A. The additional 2030 notes give Harrow more financial flexibility to fund growth initiatives, product development, and future business development opportunities without issuing new equity. We’ll now examine how this US$50,000,000 senior unsecured notes issuance...

Yahoo Finance
Mar 3rd, 2026
Harrow misses Q4 earnings estimate by 34.5% despite revenue beat

Harrow reported fourth-quarter earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.40 per share, representing a 34.46% negative surprise. This compares to earnings of $0.25 per share in the same period last year. The pharmaceutical and drug compounding company posted revenues of $89.09 million for the quarter ended December 2025, slightly exceeding the Zacks Consensus Estimate by 0.33% and up from $66.83 million a year earlier. Over the last four quarters, Harrow has surpassed consensus earnings estimates twice and topped revenue estimates once. Harrow shares have gained 10.6% year-to-date, outperforming the S&P 500's 0.5% gain. However, unfavorable estimate revision trends have resulted in a Zacks Rank of 4 (Sell), suggesting potential near-term underperformance.

The Associated Press
Mar 2nd, 2026
Harrow posts record Q4 revenue of $89.1M, up 33%, guides 2026 revenue to $350M–$365M

Harrow, a North American ophthalmic disease management solutions provider, reported record fourth-quarter revenue of $89.1 million, up 33% year-over-year, and full-year 2025 revenue of $272.3 million, up 36% from 2024. The company posted GAAP net income of $6.6 million in Q4 but a full-year net loss of $5.1 million. Adjusted EBITDA reached $24.2 million in Q4 and $61.9 million for the full year. Harrow generated $43.9 million in operating cash flow for 2025, compared to $22.2 million used in operations in 2024. The company provided 2026 guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA. Harrow plans to double sales teams for key products and expand commercial operations whilst advancing its development pipeline.

Stock Titan
Nov 18th, 2025
Harrow Completes Melt Pharmaceuticals Acquisition

Harrow (Nasdaq: HROW) has completed its acquisition of Melt Pharmaceuticals, adding clinical-stage candidates MELT-210, MELT-300, and MELT-400. MELT-300, a sublingual midazolam and ketamine formulation, showed statistical superiority in Phase 2 and 3 trials. Harrow plans to submit an NDA in H1 2027, targeting approval in H1 2028 and commercial launch in H2 2028. Over 800 U.S. ophthalmic institutions currently use Harrow's MKO Melt product.

TipRanks
Sep 30th, 2025
Harrow Health Secures New $40 Million Credit Facility - TipRanks.com

Harrow Health ( ($HROW) ) just unveiled an update. On September 26, 2025, Harrow, Inc. entered into a New Credit Agreement with Fifth Third Bank for a senior secure...